Where Akebia Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
In the past 3 months, 8 analysts have published their opinions on Akebia Therapeutics (NASDAQ:AKBA) stock, with an average 12-month price target of $2.16, up 33.33% from the previous average of $1.62. The majority of analysts are indifferent, with 7 out of 8 giving neutral ratings.
June 14, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Akebia Therapeutics (NASDAQ:AKBA) has an average 12-month price target of $2.16, up 33.33% from the previous average. Most analysts are neutral, with 7 out of 8 giving indifferent ratings.
The article focuses on the opinions of 8 analysts who have published their views on Akebia Therapeutics (NASDAQ:AKBA) stock in the past 3 months. The average 12-month price target has increased by 33.33% from the previous average, but the majority of analysts are neutral, with 7 out of 8 giving indifferent ratings. This suggests that there is no strong consensus on the stock's short-term price direction, leading to a neutral score.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100